Kuvura kanseri y'ibihaha bidashoboka 2026: TIL nshya & Bispecific Breakthroughs

amakuru

Amakuru

Kuvura kanseri y'ibihaha bidashoboka 2026: TIL nshya & Bispecific Breakthroughs

Ibirimwo Ihinduka rya Paradigm mu Kuvura Kanseri Y ibihaha Bidashoboka Gusobanukirwa Lymphocyte (TIL) Ubuvuzi Bispecific Antibodies: Uburyo bubiri-bwo kugereranya Uburyo bwo kugereranya Eme ...

Kuvura Kanseri y'ibihaha Isubiramo 2026: Ibishya bishya & Amabwiriza agezweho

Ibirimo Gusobanukirwa Kanseri yibihaha isubirwamo muri 2026 Amabwiriza agezweho ya NCCN yubuvuzi bwa kanseri yo mu bihaha itari mito mito ya kanseri y'ibihaha ivura ingamba za kanseri y'ibihaha isubirwamo kuri EGFR-Mutant Recu ...

Kuvura kanseri y'ibihaha Indolent 2026: Porotokole nshya yo kubaho igihe kirekire

Ibirimo Gusobanukirwa Kanseri Y ibihaha Indolent muri 2026 Ihinduka rya Paradigm: Kuva Kubagwa Ako kanya Kugenzura Igikorwa Cyane Cyane Cyane cyo Kubaga Amahitamo yo Gutera Indwara Zitera Intego T ...

Icyiciro cya 2A Kuvura Kanseri y'ibihaha 2026: Amakuru mashya ya ELCC kubijyanye no kuvura Neo-Adjuvant

Ibirimo Gusobanukirwa Icyiciro 2A Kanseri Yibihaha Ntoya Ntoya 2026 Intambwe ya ELCC mungamba za Neo-Adjuvant Ingamba zigamije kuvura abashoferi bahinduwe Icyiciro 2A Kanseri yibihaha igereranya Isesengura rya Trea ...

Icyiciro Cyinshi Kuvura Kanseri Yibihaha Kuvura 2026: Iza-bren & Tarlatamab Ibishya

Ibirimo Ubwihindurize Bwicyiciro Cyagutse Gitoya Yokuvura Kanseri Yibihaha Iza-bren: Ihinduka rya Paradigm muri Bispecific ADC Therapy Tarlatamab hamwe no kuzamuka kwa T-selile Abashinzwe umutekano no kwihanganira muri ...

Kuvura Kanseri y'ibihaha Isubiramo 2026: Ibishya bishya & Amabwiriza agezweho

Ibirimo Gusobanukirwa Kanseri yibihaha isubirwamo muri 2026 Amabwiriza agezweho ya NCCN yubuvuzi bwa kanseri yo mu bihaha itari mito mito ya kanseri y'ibihaha ivura ingamba za kanseri y'ibihaha isubirwamo kuri EGFR-Mutant Recu ...

Murugo
Imanza zisanzwe
Ibyerekeye Twebwe
Twandikire

Nyamuneka udusigire ubutumwa